keyword
MENU ▼
Read by QxMD icon Read
search

5HT2C

keyword
https://www.readbyqxmd.com/read/27738375/ziprasidone-augmentation-in-an-adolescent-with-obsessive-compulsive-disorder-a-case-report
#1
Sevcan Karakoç Demirkaya, Behiye Alyanak
Obsessive compulsive disorder (OCD) is characterized by recurrent, unwanted thoughts (obsessions) and/or repetitive behaviors (compulsions). Although selective serotonin reuptake inhibitors are widely used to treat OCD, only half of the patients respond well. Several potentiation strategies including off-label use of antipsychotics (mostly risperidone, quetiapine) have been tried. Ziprasidone is an atypical antipsychotic with the best affinity ratio of 5 HT 2A/D2 and 5HT2C/D2 receptors. There is a limited data on ziprasidone in pediatric groups...
March 1, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27600945/the-%C3%AE-1-opioid-receptor-and-5-ht2a-and-5ht2c-serotonergic-receptors-of-the-locus-coeruleus-are-critical-in-elaborating-hypoalgesia-induced-by-tonic-and-tonic-clonic-seizures
#2
Renato Leonardo de Freitas, Priscila Medeiros, Juliana Almeida da Silva, Rithiele Cristina de Oliveira, Ricardo de Oliveira, Farhad Ullah, Asmat Ullah Khan, Norberto Cysne Coimbra
It has been proposed that the post-ictal state is associated with the expression of hypoalgesia. It is clear that the projections among the periaqueductal gray matter (PAG), dorsal raphe nucleus (DRN) and locus coeruleus (LC) play a role in pain management. These mesencephalic structures have direct reciprocal opioid and monoaminergic projections to the LC that can possibly modulate post-ictal hypoalgesia. The goal of this study was to examine if LC-opioid and serotonergic/noradrenergic mechanisms signal the post-ictal hypoalgesic responses to tonic-clonic seizures produced by intraperitoneal administration of pentylenetetrazole (PTZ at 64mg/kg), causing an ionophore γ-aminobutyric acid (GABA)-mediated Cl(-) influx antagonism...
November 12, 2016: Neuroscience
https://www.readbyqxmd.com/read/27593622/h1-histamine-receptor-affinity-predicts-weight-gain-with-antidepressants
#3
Virginio Salvi, Claudio Mencacci, Francesco Barone-Adesi
Weight gain and metabolic abnormalities are extensively found in patients taking psychotropic medications. Although mainly antipsychotics have been implicated, also antidepressants carry the potential to induce weight gain, with tricyclics and mirtazapine being associated with the greatest weight gain. It has been suggested that this could be due to the different ability of antidepressants to block adrenergic, cholinergic, and histaminergic postsynaptic receptors. To date, however, the link between antidepressant-induced weight gain and their receptor affinity profile has not been established...
October 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27511837/control-of-sensory-neuron-excitability-by-serotonin-involves-5ht2c-receptors-and-ca-2-activated-chloride-channels
#4
Isabella Salzer, Enkhbileg Gantumur, Arsalan Yousuf, Stefan Boehm
Serotonin (5HT) is a constituent of the so-called "inflammatory soup" that sensitizes nociceptors during inflammation. Nevertheless, receptors and signaling mechanisms that mediate an excitation of dorsal root ganglion (DRG) neurons by 5HT remained controversial. Therefore, capsaicin-sensitive nociceptive neurons dissociated from rat DRGs were used to investigate effects of 5HT on membrane excitability and currents through ligand- as well as voltage-gated ion channels. In 58% of the neurons tested, 5HT increased action potential firing, an effect that was abolished by the 5HT2 receptor antagonist ritanserin, but not by the 5HT3 antagonist tropisetron...
November 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27503570/mechanism-of-action-of-pimavanserin-in-parkinson-s-disease-psychosis-targeting-serotonin-5ht2a-and-5ht2c-receptors
#5
Stephen M Stahl
Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.
August 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27222264/current-trends-on-antipsychotics-focus-on-asenapine
#6
REVIEW
Donatella Marazziti, Armando Piccinni, Stefano Baroni, Francesco Mungai, Silvio Presta, Federico Mucci, Liliana Dell'Osso
Over the years, both first- (FGAs) and second-generation antipsychotics (SGAs), continue to gain increasing evidence of being effective in the treatment of psychotic symptoms. Currently, they represent the first-line treatment of schizophrenia and bipolar disorder, although they are widely used in psychotic depression and other clinical conditions, such as agitation and/or behavioural disturbances. Despite representing an indispensable tool for the treatment of severe psychotic disorders, they are widely known to have a number of unwanted side effects that the clinician must be aware of, and handle carefully to provide the patient the best available treatment in the short and long-term...
2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/26655822/serotonin-increases-synaptic-activity-in-olfactory-bulb-glomeruli
#7
Julia Brill, Zuoyi Shao, Adam C Puche, Matt Wachowiak, Michael T Shipley
Serotoninergic fibers densely innervate olfactory bulb glomeruli, the first sites of synaptic integration in the olfactory system. Acting through 5HT2A receptors, serotonin (5HT) directly excites external tufted cells (ETCs), key excitatory glomerular neurons, and depolarizes some mitral cells (MCs), the olfactory bulb's main output neurons. We further investigated 5HT action on MCs and determined its effects on the two major classes of glomerular interneurons: GABAergic/dopaminergic short axon cells (SACs) and GABAergic periglomerular cells (PGCs)...
March 2016: Journal of Neurophysiology
https://www.readbyqxmd.com/read/26444951/agomelatine-for-depression-in-parkinson-disease-additional-effect-on-sleep-and-motor-dysfunction
#8
Asuncion Avila, Xavier Cardona, Montserrat Martin-Baranera, Lucia Leon, Nuria Caballol, Pablo Millet, Juan Bello
Depression and sleep disorders are among the most prevalent nonmotor symptoms of Parkinson disease (PD). Because agomelatine acts as a MT1 and MT2 agonist and as a 5HT2c antagonist, this study was designed to assess the efficacy of agomelatine in treating depressive symptoms in PD patients, and the potential changes both in sleep quality and motor symptoms. Depressed patients with PD were treated with agomelatine for 6 months, and they were evaluated with an array of scales. Completed nocturnal video-polysomnography was performed at baseline and week 12...
December 2015: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/26346394/horizons-in-the-pharmacotherapy-of-obesity
#9
REVIEW
Jonathan R S Arch
Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators' caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets...
December 2015: Current Obesity Reports
https://www.readbyqxmd.com/read/26255180/preclinical-characterization-of-toluene-as-a-non-classical-hallucinogen-drug-in-rats-participation-of-5-ht-dopamine-and-glutamate-systems
#10
María Teresa Rivera-García, Carolina López-Rubalcava, Silvia L Cruz
RATIONALE: Toluene is a misused inhalant with hallucinogenic properties and complex effects. Toluene blocks N-methyl-D-aspartate (NMDA) receptors, releases dopamine (DA), and modifies several neurotransmitter levels; nonetheless, the mechanism by which it produces hallucinations is not well characterized. OBJECTIVES: This study aims (a) to study toluene's effects on the 5-HT2A-mediated head-twitch response (HTR), dopamine (DA), and serotonin (5-HT) tissue levels in discrete brain regions; (b) to compare the actions of toluene, ketamine, and 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) on HTR; and (c) to study the pharmacological blockade of toluene's and ketamine's effects by selective drugs...
October 2015: Psychopharmacology
https://www.readbyqxmd.com/read/26174133/does-melatonin-treatment-change-emotional-processing-implications-for-understanding-the-antidepressant-mechanism-of-agomelatine
#11
Abbie Pringle, Maria Bogdanovskaya, Poppy Waskett, Sophie Zacharia, Philip J Cowen, Catherine J Harmer
The antidepressant, agomelatine, has a novel pharmacological profile, with agonist properties at M1 and M2 receptors and antagonist properties at 5HT2C receptors. Whether the antidepressant effects of this treatment are mediated by the drug's effects at the M1 and M2 receptors or the 5HT2C receptor or a synergy between these actions remains unclear. In the present study, a healthy volunteer model of emotional processing, which discriminates between effective and non-effective antidepressant compounds, was used to assess the contribution of melatonin agonism to the efficacy of agomelatine...
October 2015: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26111577/lurasidone-in-the-treatment-of-schizophrenia-a-critical-evaluation
#12
REVIEW
Dawn Bruijnzeel, Mehdi Yazdanpanah, Uma Suryadevara, Rajiv Tandon
INTRODUCTION: Antipsychotic medications are the foundation of the pharmacological treatment of schizophrenia and lurasidone is the most recent of the 65 agents around the world to become available. In order to use it optimally, it is important to understand its pharmacological and clinical nature and its comparative effectiveness to other antipsychotic agents in the treatment of schizophrenia. AREAS COVERED: Following a comprehensive review of the literature, this article summarizes current information about the pharmacology of lurasidone, data about its short- and long-term efficacy and safety/tolerability in the treatment of schizophrenia, its comparative effectiveness to other antipsychotic agents, and guidance about its optimal use in the treatment of individuals with schizophrenia...
2015: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/25980223/-agonists-of-5ht2c-receptors-sch-23390-and-mk-212-incresase-the-force-of-rat-aorta-contraction-in-the-presence-of-vasopressin-and-angiotensin-ii
#13
L M Kozhevnikova, M V Mesitov, A A Moskovtsev
We investigated the role of 5HT2C receptors in regulation of blood vessel contractility. We determined expression of 5HT2C receptors in smooth muscle cell line A7r5 as well as on isolated rat aorta. It was shown that strong vasoconstriction effect of 5HT2C receptor agonists - SCH 23390 and MK 212 appeared on blood vessels after preliminary activation of angiotensin ATIA- and vasopressin V1A-receptors. Biphasic contraction (a rhythmic alternation of contraction and subsequent relaxation phases of aoitic rings) and tonic contraction were observed in 75% and 25% of the cases after 5HT2C receptor activation, respectively...
October 2014: Patologicheskaia Fiziologiia i èksperimental'naia Terapiia
https://www.readbyqxmd.com/read/25904865/voltage-sensing-phosphatase-modulation-by-a-c2-domain
#14
Paul M Castle, Kevin D Zolman, Susy C Kohout
The voltage-sensing phosphatase (VSP) is the first example of an enzyme controlled by changes in membrane potential. VSP has four distinct regions: the transmembrane voltage-sensing domain (VSD), the inter-domain linker, the cytosolic catalytic domain, and the C2 domain. The VSD transmits the changes in membrane potential through the inter-domain linker activating the catalytic domain which then dephosphorylates phosphatidylinositol phosphate (PIP) lipids. The role of the C2, however, has not been established...
2015: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/25893641/acute-effects-of-the-designer-drugs-benzylpiperazine-bzp-and-trifluoromethylphenylpiperazine-tfmpp-using-functional-magnetic-resonance-imaging-fmri-and-the-stroop-task-a-pilot-study
#15
Louise E Curley, Rob R Kydd, Michelle C Robertson, Avinesh Pillai, Nicolas McNair, HeeSeung Lee, Ian J Kirk, Bruce R Russell
RATIONALE: A novel group of designer drugs containing benzylpiperazine (BZP) and/or trifluoromethylphenylpiperazine (TFMPP) have been available worldwide for more than a decade; however, their effects on human brain function have not been extensively described. OBJECTIVES: In a double-blind, placebo-controlled crossover study, the acute effects of BZP and TFMPP (alone and in combination) on the neural networks involved in executive function were investigated using an event-related Stroop functional magnetic resonance imaging (fMRI) paradigm...
August 2015: Psychopharmacology
https://www.readbyqxmd.com/read/25784603/hippocampal-transcriptional-and-neurogenic-changes-evoked-by-combination-yohimbine-and-imipramine-treatment
#16
Basma Fatima Anwar Husain, Ishira N Nanavaty, Swananda V Marathe, Rajeev Rajendran, Vidita A Vaidya
Adjunct α2-adrenoceptor antagonism is a potential strategy to accelerate the behavioral effects of antidepressants. Co-administration of the α2-adrenoceptor antagonist yohimbine hastens the behavioral and neurogenic effects of the antidepressant imipramine. We examined the transcriptional targets of short duration (7days), combination treatment of yohimbine and imipramine (Y+I) within the adult rat hippocampus. Using microarray and qPCR analysis we observed functional enrichment of genes involved in intracellular signaling cascades, plasma membrane, cellular metal ion homeostasis, multicellular stress responses and neuropeptide signaling pathways in the Y+I transcriptome...
August 3, 2015: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/25720289/-the-effects-of-inhibitors-of-rho-and-tyrosine-c-src-kinases-on-serotonin-induced-constrictions-of-the-aorta-and-mesenteric-artery-in-rats
#17
L M Kozhevnikova, A A Moskovtsev, M V Mesitov
We found that the inhibitor of Rho-kinase fasudil selectively inhibited constriction of isolated rings of the aorta and mesenteric artery in rats in response to application of the agonists of 5HT2A-(DOI and TBC-2) and 5HT1A-receptors (8-OH-DPAT) and did not influence vasoconstriction induced by serotonin. We demonstrate for the first time that application of the agonists of 5HT2C-receptors (MK 212 and SCH 23390) did not influence the tone of "intact" vessels. The marked vasoconstrictory effect of the agonists of 5HT2C-receptors was observed in the vessels preconstricted due to angiotensin II or vasopressin...
September 2014: Izvestiia Akademii Nauk. Seriia Biologicheskaia
https://www.readbyqxmd.com/read/25563411/safety-assessment-of-fda-approved-orlistat-and-lorcaserin-anti-obesity-medications
#18
REVIEW
Bruno Halpern, Alfredo Halpern
INTRODUCTION: Options for treating obesity remain limited despite it being a chronic, recurrent and morbid condition. New drugs that are proposed for its treatment encounter strong reluctance by regulatory agencies and many doctors. AREAS COVERED: This review will focus on the safety of an older drug, orlistat (the only one still approved in the European Union) and a newer recently FDA-approved one, lorcaserin. Both are approved as long-term monotherapy for obesity in the United States of America and they have demonstrated median weight loss of nearly 3% over placebo...
February 2015: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/25453735/-short-term-efficacy-and-safety-of-lurasidone-in-the-treatment-of-schizophrenia
#19
REVIEW
L Samalin, M Ben Gharbia, M Garnier, P-M Llorca
Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration and in March 2014 by the European Medicines Agency for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is an antagonist of D2 dopamine and 5HT2A serotonin receptors, but differs from the other second-generation antipsychotics in its action profile for certain receptors. Lurasidone is the second-generation antipsychotic with the greatest affinity for 5HT7 receptors and has a low affinity for α1 and α2C-adrenergic and 5HT2C serotonin receptors, and no affinity for histaminergic H1 or muscarinic M1 receptors...
December 2014: L'Encéphale
https://www.readbyqxmd.com/read/25449893/effects-of-risperidone-treatment-on-the-expression-of-hypothalamic-neuropeptide-in-appetite-regulation-in-wistar-rats
#20
Canan Kursungoz, Mehmet Ak, Tulin Yanik
Although the use of atypical antipsychotic drugs has been successful in the treatment of schizophrenia, they can cause some complications in the long-term use, including weight gain. Patients using these drugs tend to disrupt treatment primarily due to side effects. The atypical antipsychotic mechanism of action regulates a number of highly disrupted neurotransmitter pathways in the brains of psychotic patients but may also cause impairment of neurohormonal pathways in different brain areas. In this study, we investigated the circulating levels of hypothalamic neurohormones, which are related to appetite regulation; neuropeptide Y (NPY); alpha melanocyte stimulating hormone (α-MSH); cocaine and amphetamine regulated transcript (CART); agouti-related peptide (AgRP); and leptin in male Wistar rats, which were treated with risperidone, a serotonin antagonist, for four weeks...
January 30, 2015: Brain Research
keyword
keyword
71421
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"